Life Sci Turns 5


Clients in the media Clients IN the MEDIA

Ensuring your story is visible.

The 9 Things Wildly Successful Biotechs Have in Common

“You can’t just have great scientists. You also need great managers and staff who will build culture,” Sung You, managing partner at PBM Capital and chief business officer at SalioGen Therapeutics, said. 


Launching of Early-Phase Trial May Mark a ‘Major Milestone’ for Improving Gastric and Pancreatic Cancer Treatment

The first patient has been dosed in the ongoing phase 1/2 CLAUDIO-01 clinical trial examining a new antibody drug conjugate called SOT102 in patients with gastric and pancreatic cancer, according to SOTIO, the manufacturer of the drug.

tech nation radio

Episode 22-17 Stopping Breast Cancer Before It Starts? on Apple Podcasts

Dr. Amit Kumar, the President and CEO of Anixa Biosciences, about a new approach to actually preventing the truly aggressive triple negative breast cancer, and its potential for other breast cancers and ovarian cancer.


Windtree is Bringing Patients Back from Cardiogenic Shock in Phase II

New data unveiled by Windtree Therapeutics shows significant promise in heart failure patients who have deteriorated into cardiogenic shock.


TCR Search-and-Capture: Working Toward Personalized Cancer Therapy

Cell and gene therapy is not immune to the personalized medicine trend, and BlueSphere Bio hopes its leading T-cell receptor engineering (TCR) platform, along with its TCX-101 clinical candidate, can ultimately bolster the armamentarium for patients with hematologic malignancies and solid tumors.


AACR: Advances in Immune System Stimulation and Cell Transplants Favor Oncology

BlueSphere Bio, for example, is trying to improve the efficacy of allogeneic stem cell transplant (alloSCT) treatments for patients with hematologic malignancies and solid tumors using its T-cell receptor (TCR) discovery platform. That platform, TCXpress™, identifies TCRs that may be especially efficacious against some of the most challenging types of cancer.


Aadi, SOTIO and Ikena Target Cancer-Causing Mutations at AACR  

SOTIO, a biotech company based in Prague and Cambridge, MA, focuses on improving CAR-T therapies and stable antibody-drug conjugates (ADCs). In its poster presentation, SOTIO announced preclinical data on its immunocytokine SOT201 and the BOXR CAR-T cell therapy BOXR1030. The company’s focus, however, was on its oral presentation featuring SOT101. 


Commensal Viral Vectors With Ring Therapeutics’ Tuyen Ong, M.D.

Today, he’s CEO of Ring Therapeutics, a promising emerging biotech backed by Flagship Pioneering